Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury

Abstract

Growing evidence has shown that gut microbiome is a key factor involved in liver health. Therefore, gut microbiota modulation with probiotic bacteria, such as Saccharomyces boulardii, constitutes a promising therapy for hepatosis. In this study, we aimed to investigate the protective effects of S. boulardii on D-Galactosamine-induced liver injury in mice. Liver function test and histopathological analysis both suggested that the liver injury can be effectively attenuated by S. boulardii administration. In the meantime, S. boulardii induced dramatic changes in the gut microbial composition. At the phylum level, we found that S. boulardii significantly increased in the relative abundance of Bacteroidetes, and decreased the relative abundance of Firmicutes and Proteobacteria, which may explain the hepatic protective effects of S. boulardii. Taken together, our results demonstrated that S. boulardii administration could change the gut microbiota in mice and alleviate acute liver failure, indicating a potential protective and therapeutic role of S. boulardii.

Administration of Saccharomyces boulardii mafic-1701 improves growth performance, promotes antioxidant capacity, alleviates intestinal inflammation and modulates gut microbiota in weaned piglets

“…Namely, the composition and structure of the microbiota was greatly affected by diet. From the results of phylum analysis, we found that the cecum microbial floras were dominated by Firmicutes, this was consistent with previous finding reported by Lei Yu [31]. Whereas colon microbiota communities were dominated by Firmicutes and Proteobacteria, regardless of diet treatment.…”

Commensal Fungi in Health and Disease

“…Interestingly, the investigators noted that these three organisms can be coaxed into forming a mixed biofilm which they hypothesize could facilitate their co-colonization of the intestines. It has also been reported in an animal model that S. boulardii interacts with and alters commensal bacterial microbiota (Yu et al, 2017) (Figure 1). Similarly, a recent study demonstrated that oral administration of the dietary yeast Candida kefyr (also known as Candida pseudotropicalis or Kluyveromyces marxianus ) was protective in mouse models of colitis and experimental autoimmune encephalomyelitis (Takata et al, 2015).…”

Fungal Dysbiosis and Intestinal Inflammation in Children With Beta-Cell Autoimmunity

“…The potency of the mycobiota to regulate the bacterial compartment is suggested by animal studies showing that restoration of the bacterial compartment after antibiotic depletion of bacteria was strongly influenced by colonization with C. albicans (62). In a mouse model of liver injury, administration of Saccharomyces boulardii changed the composition of intestinal bacterial compartment by increasing the relative abundance of Bacteroidetes and decreasing the relative abundance of the bacteria belonging to the Firmicutes (63). Interestingly, Enterobacteriaceae, such as Escherichia coli has been shown to cooperate with yeast to favor their colonization and inflammatory properties in the intestine in an animal model of ulcerative colitis (64).…”